Polatuzumab vedotin (Polivy®) HTA ID: 19052
Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).
| NCPE Assessment Process | Complete |
| Rapid Review commissioned | 03/12/2019 |
| Rapid Review completed | 27/01/2020 |
| Rapid Review Outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 26/02/2020 |
| Pre-submission consultation with Applicant | 31/03/2020 |
| Full submission received from Applicant | 10/07/2020 |
| Preliminary review sent to Applicant | 27/10/2020 |
| NCPE assessment re-commenced | 25/11/2020 |
| Factual accuracy check sent to Applicant | 26/01/2021 |
| NCPE assessment re-commenced | 02/02/2021 |
| NCPE assessment completed | 16/02/2021 |
| NCPE assessment outcome | The NCPE recommends that polatuzumab vedotin (Polivy®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.